フォロー
Pelin Gülizar Ersan
Pelin Gülizar Ersan
Postdoctoral Researcher, Biotech Research and Innovation Centre (BRIC), University of Copenhagen
確認したメール アドレス: bric.ku.dk
タイトル
引用先
引用先
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
O Saatci, A Kaymak, U Raza, PG Ersan, O Akbulut, CE Banister, ...
Nature communications 11 (1), 2416, 2020
2022020
The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer
U Raza, Ö Saatci, S Uhlmann, SA Ansari, E Eyüpoğlu, E Yurdusev, ...
Oncotarget 7 (31), 49859, 2016
582016
Reactivation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer
RR Mishra, N Belder, SA Ansari, M Kayhan, H Bal, U Raza, PG Ersan, ...
Clinical Cancer Research 24 (8), 1987-2001, 2018
472018
Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers
A Siddiqui, PN Gollavilli, A Schwab, ME Vazakidou, PG Ersan, ...
Cell Death & Differentiation 26 (11), 2223-2236, 2019
362019
Systems-level Analysis Reveals Multiple Modulators of Epithelial-mesenchymal Transition and Identifies DNAJB4 and CD81 as Novel Metastasis Inducers in Breast Cancer*[S]
ZCU Kagiali, E Sanal, Ö Karayel, AN Polat, Ö Saatci, PG Ersan, K Trappe, ...
Molecular & Cellular Proteomics 18 (9), 1756-1771, 2019
312019
Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer
R Assidicky, UM Tokat, IO Tarman, O Saatci, PG Ersan, U Raza, H Ogul, ...
Breast cancer research and treatment 193 (2), 331-348, 2022
222022
Targeting adenosine with adenosine deaminase 2 to inhibit growth of solid tumors
L Wang, LM Londono, J Cowell, O Saatci, M Aras, PG Ersan, S Serra, ...
Cancer Research 81 (12), 3319-3332, 2021
202021
TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice
M Yildirim, TC Yildirim, N Turay, T Bildik, B Ibibik, I Evcili, PG Ersan, ...
Immunology Letters 239, 32-41, 2021
152021
The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer. Oncotarget. 2016; 7 …
U Raza, O Saatci, S Uhlmann, SA Ansari, E Eyüpoğlu, E Yurdusev, ...
5
Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer
O Saatci, M Cetin, M Uner, UM Tokat, I Chatzistamou, PG Ersan, ...
Nature Communications 14 (1), 6997, 2023
12023
EACR-MRS conference on seed and soil: in vivo models of metastasis
I Teles Alves, N Cohen, PG Ersan, R Eyre, I Godet, D Holovanchuk, ...
Clinical & Experimental Metastasis 34, 449-456, 2017
12017
Abstract A008: Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer
O Saatci, M Cetin, M Uner, UM Tokat, I Chatzistamou, PG Ersan, ...
Cancer Research 84 (1_Supplement), A008-A008, 2024
2024
Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer
O Saatci, R Alam, KT Huynh-Dam, A Isik, M Uner, N Belder, PG Ersan, ...
bioRxiv, 2023.11. 05.565697, 2023
2023
Overcoming tamoxifen resistance and inhibiting metastatic recurrence in estrogen receptor-positive breast cancer
PG Ersan, O Saatci, O Tarman, R Mishra, N Belder, UM Tokat, ...
Cancer Research 79 (13_Supplement), 2121-2121, 2019
2019
Thymidylate synthase maintains the de-differentiated state of aggressive breast cancers
A Siddiqui, P Gollavilli, A Schwab, ME Vazakidou, PG Ersan, ...
bioRxiv, 321943, 2018
2018
Identifying and targeting competing endogenous RNA (ceRNAs) networks to inhibit lung metastasis in triple negative breast cancer
P Ersan, U Tokat, E Eyupoglu, U Raza, Y Riazalhosseini, C Alkan, ...
Cancer Research 77 (13_Supplement), 2848-2848, 2017
2017
Competing endogenous RNA (ceRNAs) interaction network regulating lung metastasis in triple negative breast cancer
PG Ersan, UM Tokat, E Eyupoglu, U Raza, Y Riazalhosseini, C Alkan, ...
2017
TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice
M Yıldırım, TC Yıldırım, N Turay, T Bildik, B İbibik, İ Evcili, PG Ersan, ...
Elsevier BV, 0
Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer
UM Tokat, IO Tarman, PG Ersan, U Raza, O Saatci, O Sahin, H Ogul, ...
Springer New York LLC, 0
The role of mediator complex in tamoxifen resistance of ER-positive breast cancer
PG Ersan
Bilkent University, 0
現在システムで処理を実行できません。しばらくしてからもう一度お試しください。
論文 1–20